Boston Scientific’s VITALYST heart-pump programme has a development-funding agreement worth up to US$455 million with Blackstone. The company’s public filing ties that ceiling to qualifying development costs through US regulatory approval, unless the arrangement ends earlier. The figure describes potential funding under an agreement, rather than a payment already received or a completed approval. Boston Scientific’s disclosure

What the programme is developing

VITALYST is a temporary mechanical circulatory-support pump. MedTech Dive’s 5 November account describes Boston Scientific’s development focus as acute myocardial infarction with cardiogenic shock: a heart attack accompanied by severe failure of the heart’s pumping function. That identifies the proposed clinical setting; it does not establish how well the device performs there. MedTech Dive’s development report

Read the funding and repayment conditions together

The filing says the agreement was entered on 2 October 2026. Its “Funded Research and Development Arrangement” section describes cost-based funding from Blackstone and potential payments in the other direction.

Subject to US regulatory approval, Blackstone would be eligible for fixed regulatory and commercial milestone payments of up to 2.5 times the amount it actually funds, plus royalties on net sales. The commercial milestone also depends on a specified cumulative sales target. The filing’s funding terms

The distinction between a ceiling and actual funding matters on both sides. Multiplying the headline ceiling would not describe an unconditional payment obligation. Approval and commercial milestones remain part of the arrangement’s disclosed conditions.

Funding advances a programme; results answer another question

The agreement explains who can share development costs and participate in later commercial returns. It supplies no clinical comparison from which to judge patient benefit or select a pump.

For professionals following device development, the next evidence milestones are therefore the programme’s actual studies, results and regulatory decisions. A financing announcement can support continued development while leaving those questions open.